Dr Reddys Laboratories (RDY) Research & Development (2009 - 2026)
Dr Reddys Laboratories (RDY) reported Research & Development of $60.9 million for the quarter ended Jun 30, 2026, down 16.5% from $72.96 million a year earlier but up 1.9% from the prior quarter.
Dr Reddys Laboratories (RDY) Research & Development (2009 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Dr Reddys Laboratories' Research & Development came in at $260.82 million, down 19.1% year-over-year; for the year ended Mar 31, 2026, it was $256 million, down 20.0% from the prior year.
- Research & Development has a five-year compound annual growth rate of 2.5% (years ended Mar 2021 to Mar 2026).
- By year, Research & Development came in at $320 million in the year ended Mar 31, 2025 (+16.8%), $274 million in the year ended Mar 31, 2024 (+16.1%), $236 million in the year ended Mar 31, 2023 (+2.6%) and $230 million in the year ended Mar 31, 2022 (+1.8%).
- Five-year quarterly Research & Development spans a low of $55 million in the quarter ended Sep 30, 2021 and a high of $86.81 million in the quarter ended Sep 30, 2024.
- Year over year, Research & Development has now declined in each of the last five quarters, with an average decline of 3.3% over the last eight quarters.
- The high point for year-over-year Research & Development in five years was the quarter ended Mar 31, 2024 (growth of 38.0%); the low point was the quarter ended Mar 31, 2026 (a decline of 28.7%).
- Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at $59.76 million (quarter ended Mar 31, 2026), $69.05 million (quarter ended Dec 31, 2025) and $71.1 million (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Dr Reddys Laboratories | 10.44 Bn | 9.62 Bn | 396.53 Mn | 60.90 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 60.90 Mn |
| Mar 31, 2026 | 59.76 Mn |
| Dec 31, 2025 | 69.05 Mn |
| Sep 30, 2025 | 71.10 Mn |
| Jun 30, 2025 | 72.96 Mn |
| Mar 31, 2025 | 83.82 Mn |
| Dec 31, 2024 | 78.86 Mn |
| Sep 30, 2024 | 86.81 Mn |
| Jun 30, 2024 | 74.24 Mn |
| Mar 31, 2024 | 82.81 Mn |
| Dec 31, 2023 | 66.84 Mn |
| Sep 30, 2023 | 65.89 Mn |
| Jun 30, 2023 | 66.00 Mn |
| Mar 31, 2023 | 60.00 Mn |
| Dec 31, 2022 | 65.00 Mn |
| Sep 30, 2022 | 59.00 Mn |
| Jun 30, 2022 | 56.09 Mn |
| Mar 31, 2022 | 57.53 Mn |
| Dec 31, 2021 | 57.00 Mn |
| Sep 30, 2021 | 55.00 Mn |
Dr Reddys Laboratories Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=RDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "RDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=RDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();